Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call. [Operator Instructions] As a remind ...

Company Performance - Artivion reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and compared to earnings of $0.02 per share a year ago, representing an earnings surprise of 200% [1] - The company posted revenues of $97.43 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 5.56%, and compared to year-ago revenues of $83.23 million [1] - Artivion has surpassed consensus EPS estimates four times over the last four quarters [1] Stock Movement and Outlook - Artivion shares have increased approximately 17.1% since the beginning of the year, outperforming the S&P 500's gain of 7.5% [2] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [2] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $98.25 million, and for the current fiscal year, it is $0.26 on revenues of $388.9 million [4] Industry Context - The Medical - Instruments industry, to which Artivion belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [5] - Another company in the same industry, Penumbra, is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year change of +82.6%, with revenues expected to be $274.82 million, up 13.8% from the year-ago quarter [5][6]

Exhibit 99.1 FOR IMMEDIATE RELEASE | --- | |----------------------------| | | | | | Contacts: | | Artivion | | Lance A. Berry | | Executive Vice President & | | Chief Financial Officer | | Phone: 770-419-3355 | Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 investors@artivion.com Artivion Reports First Quarter 2024 Financial Results First Quarter Highlights: • Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase ...

5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA, April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low ...

ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 10:15 a.m. ET on Monday, April 8, 2024. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of ...

Core Viewpoint - Artivion (AORT) has shown strong stock performance, with a 9.6% increase over the past month and an 18.3% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Instruments industry [1][2]. Financial Performance - Artivion has consistently exceeded earnings expectations, reporting an EPS of $0.11 against a consensus estimate of $-0.13 in its last earnings report [2]. - For the current fiscal year, Artivion is projected to achieve earnings of $0.26 per share on revenues of $388.9 million, reflecting a 30% increase in EPS and a 9.86% increase in revenues [2]. - The next fiscal year forecasts earnings of $0.58 per share on revenues of $427.05 million, indicating a year-over-year change of 123.08% in EPS and 9.81% in revenues [2]. Valuation Metrics - Artivion's current trading metrics show a P/E ratio of 81.4X for the current fiscal year, significantly higher than the peer industry average of 27X [4]. - On a trailing cash flow basis, Artivion trades at 27.5X compared to the peer group's average of 15X, suggesting a premium valuation [4]. - The stock has a Value Score of C, a Growth Score of B, and a Momentum Score of D, resulting in a combined VGM Score of B [3]. Zacks Rank - Artivion holds a Zacks Rank of 1 (Strong Buy), driven by rising earnings estimates, making it a favorable investment choice [5]. - The recommendation is to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, which applies to Artivion [5]. Industry Comparison - In comparison to industry peers, Tactile Systems Technology, Inc. (TCMD) also shows strong performance with a Zacks Rank of 2 (Buy) and robust earnings growth [6]. - TCMD is expected to post earnings of $0.56 per share on revenues of $302.89 million for the current fiscal year, with a recent earnings surprise of 192.31% [6]. - The Medical - Instruments industry is performing well, ranking in the top 22% of all industries, providing a favorable environment for both AORT and TCMD [6].

As many know, small-caps’ volatile nature can sometimes turn investors away.However, many small-cap stocks turn out to be big winners in the long run, and they typically have fewer eyes on them, providing investors an opportunity to get in "early" before the crowd.For those seeking exposure to small-caps, three stocks – EZCORP (EZPW) , Artivion (AORT) , and QuickLogic (QUIK) – could all be considered.All three sport a favorable Zacks Rank, indicating optimism among analysts. Let’s take a closer look at each ...

The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth.The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and mi ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Artivion is a member of our Medical group, which includes 1066 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges th ...

ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived ...